Cell and Gene Commercialization

31. Understanding CLL And SLL Treatment Evolution 10/10/2025

    Tevogen Bio's Dr. Neal Flomenberg and Dr. Dolores Grosso discuss the shift from chemotherapy to targeted therapies such as Jaypirca and highlight Tevogen’s antigen-specific T cell platform as a new frontier in cancer and infectious disease treatment.

32. Know Your Product, Know Your Path: A Primer On Advanced Therapy Development 10/9/2025

    To prevent path-to-market setbacks, it is critical to develop a Chemistry, Manufacturing, and Controls strategy that proactively identifies scientific and compliance gaps, as well as mitigates risk.

33. How Strategic CMC Planning Drives Cell Therapy Success 10/7/2025

    Here, we identify twelve critical CMC challenges that frequently threaten cell therapy development programs and provide practical strategies to overcome them.

34. Scaling Allogeneic NK Cell Therapies 10/1/2025

    In this segment of Cell & Gene Live, Building the Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation, Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, highlighted the allogeneic, off-the-shelf nature of their NK cell therapy. Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics expressed strong confidence that NK cell therapies can be produced at a fraction of the cost of autologous treatments, making them widely accessible and commercially viable.

35. Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit 9/26/2025

    OS Therapies' Dr. Robert Petit discusses the evolving role of immunotherapy in prostate cancer.

36. A Study In Optimizing Late-Stage Processes With QbD, DoE 9/26/2025

    Nobody wants to redesign analytical process profiles when a market approval is within reach, but what about when a last-lap QbD exercise could bring real benefit?

37. On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D. 9/25/2025

    DeciBio partner Carl Schoellhammer, Ph.D., speaks on the record with Bioprocess Online's chief editor Tyler Menichiello at the 2025 BioProcess International conference in Boston.

38. Navigating Commercial Logistics For CGTs: A Roadmap To Scalable, Patient-Centered Success 9/24/2025

    The commercialization of cell and gene therapies requires a precise and resilient logistics model that can adapt to rapid demand and global expansion while maintaining a patient-first approach.

39. Building The Future Of Cancer Immunotherapy Through Allogeneic NK Cell Innovation 9/18/2025

    As the cell therapy space evolves beyond T cells, allogeneic natural killer (NK) cell therapies are emerging as a scalable and accessible approach in cancer immunotherapy. Cell & Gene's Chief Editor, Erin Harris, welcomed experts Raphael Ognar, President, CEO, and Co-Founder of NKILT Therapeutics, and Tracy Ryan, Co-Founder and Chief Communications Officer of NKore BioTherapeutics, for a detailed discussion exploring how their teams are advancing the field through distinct yet complementary strategies. The dynamic discussion highlighted the scientific innovation, technological differentiation, and patient-centered vision driving the next generation of allogeneic NK cell therapies, and why now is the critical moment to deepen research and exploration into novel NK platforms.

40. 2024 Cell And Gene Therapy Report: Advancing The Future Of Medicine 9/2/2025

    Cell and gene therapies offer hope for cures, but face significant barriers to broader patient access. Find out how industry leaders are working to overcome these challenges.